Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other financing activities: 2010-2025

Historic Other financing activities for Ironwood Pharmaceuticals (IRWD) over the last 6 years, with Sep 2025 value amounting to $1,000.

  • Ironwood Pharmaceuticals' Other financing activities rose 100.01% to $1,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year increase of 131.56%. This contributed to the annual value of $11.0 million for FY2024, which is 174.98% up from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Other financing activities of $1,000 as of Q3 2025, which was down 98.86% from $88,000 recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Other financing activities ranged from a high of $17.5 million in Q4 2021 and a low of -$8.7 million during Q3 2024.
  • Its 3-year average for Other financing activities is $1.4 million, with a median of $750,000 in 2024.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Other financing activities soared by 887.76% in 2021, and later tumbled by 66,676.92% in 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' Other financing activities (Quarterly) stood at $17.5 million in 2021, then plummeted by 70.44% to $5.2 million in 2022, then crashed by 66.85% to $1.7 million in 2023, then soared by 417.95% to $8.9 million in 2024, then soared by 100.01% to $1,000 in 2025.
  • Its last three reported values are $1,000 in Q3 2025, $88,000 for Q2 2025, and $6,000 during Q1 2025.